Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting
The data, which will be presented in both a poster discussion session and a poster session, show that SY-1365 has significant anti-tumor activity in multiple models of treatment-resistant ovarian cancer. The data also identify potential biomarkers of response to SY-1365. Syros plans to open expansion cohorts in mid-2018 in its ongoing Phase 1 trial to evaluate SY-1365 in patients with ovarian cancer, as well as to evaluate these potential biomarkers (ClinicalTrials.gov identifier: NCT03134638).
Details on the presentations are as follows:
Presentation Title: SY-1365, a selective CDK7 inhibitor, exhibits potent anti-tumor activity against ovarian cancer models in vitro and in vivo
Session Category: Molecular and Cellular Biology/Genetics
Presenter: Panagiotis A. Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute
Abstract Number: 1343
Poster Discussion Session
Date & Time: Sunday, April 15, 4:00 p.m. - 5:00 p.m. CDT
Session Title: Targeting the Cell Cycle: Mechanism and Therapy – Poster Discussion
Location: McCormick Place South, Level 4, Room S402
Date and Time: Monday, April 16, 8:00 a.m. - 12:00 p.m. CDT
Session Title: Targeting the Cell Cycle: Mechanism and Therapy
Poster Session Location: McCormick Place South, Exhibit Hall A, Poster Section 23
About Syros Pharmaceuticals
Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.